Nomura’s June 2025 analysis shows Indian pharma majors like Sun Pharma, Dr. Reddy’s, Cipla, Lupin, and Zydus posting strong ...

Cipla shares broke out above ₹1,580–₹1,590 on strong volumes, with technical indicators signaling further gains.

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

CHENNAI: Indian equity markets ended Thursday’s session with modest gains, supported by financials and Reliance Industries, ...

With semaglutide patents set to expire in 2026, Indian pharma giants are ramping up peptide production and device tie-ups to ...

An update from Theravance Biopharma ( ($TBPH) ) is now available. On August 15, 2025, Theravance Biopharma and Mylan entered into a Settlement ...

Zee Business analysts Ansh Jogendra Bhilwar and Pooja Tripathi have shared a number of calls for trading and investing today, ...

Cipla Ltd is quoting at Rs 1566.2, up 2.93% on the day as on 12:49 IST on the NSE. The stock is up 0.15% in last one year as compared to a 1.99% spurt in NIFTY and a 0.67% spurt in the Nifty Pharma ...

With sweeping duties taking effect Aug. 27, India faces billions in losses, mass job cuts, and shrinking competitiveness in ...

Union Commerce and Industry Minister Piyush Goyal has discussed strategies to boost competitiveness and strengthen research and development activities with the business representatives of the ...

According to Elara Capital’s Domestic Liquidity Tracker, the changes in pharma and tech were led by HDFC MF, ICICI Prudential MF, and SBI Mutual Fund.

The market is expected to consolidate further as long as the frontline indices continue trading below their medium-term moving averages. Below are some short-term trading ideas to consider.